LGND — Ligand Pharmaceuticals Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual balance sheet for Ligand Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	1,070	411	341	212	170
Net Total Accounts Receivable
Net Total Receivables	41.7	59.1	91.6	35	39.3
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	1,124	501	465	264	237
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	17.5	37.2	53.3	27.5	25.1
Net Goodwill
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	1,495	1,362	1,298	763	787
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	17	100	41.7	98.8	16.8
Long Term Debt
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Other Liabilities
Total Liabilities	728	653	476	165	86.3
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	767	710	821	597	701
Total Liabilities & Shareholders' Equity	1,495	1,362	1,298	763	787
Total Common Shares Outstanding